<?xml version="1.0" encoding="utf-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title><![CDATA[Zoomedia, Inc.: Client News]]></title>
    <link>http://www.zoomedia.com/client_news/client_news_rss</link>
    <description><![CDATA[Zoomedia, Inc. : Client News]]></description>
    <pubDate>Fri, 16 Aug 2013 19:42:57 +0000</pubDate>
    <managingEditor>webmaster@zoomedia.com (Zoomedia Inc.)</managingEditor>
    <copyright>Zoomedia Inc.</copyright>
    <generator>Zoomedia CMS</generator>
    <language>en</language>
    <docs>http://blogs.law.harvard.edu/tech/rss</docs>
    <item>
      <title><![CDATA[Regeneron Announces First Recipients of Annual &quot;Regeneron Prize for Creative Innovation&quot;]]></title>
      <link>http://investor.regeneron.com/releasedetail.cfm?ReleaseID=774355</link>
      <description><![CDATA[Regeneron Announces First Recipients of Annual "Regeneron Prize for Creative Innovation"]]></description>
      <pubDate>Thu, 27 Jun 2013 20:30:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders]]></title>
      <link>http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&amp;p=RssLanding&amp;cat=news&amp;id=1833323</link>
      <description><![CDATA[SEATTLE, June 27, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced results from its Annual Meeting of Shareholders held on Wednesday, June 26, 2013.

At the Annual Meeting, shareholders elected John H. Bauer, Phillip M. Nudelman, Ph.D., and Reed V. Tuckson, M.D. to serve on the Company's Board of Directors until the Company's 2016 Annual Meeting. Shareholders approved an amendment to the Company's amended and restated articles of incorporation to increase the total number of authorized shares and authorized shares of common stock and approved an amendment to the Company's 2007 Equity Incentive Plan, as amended and restated, to increase the number of...]]></description>
      <pubDate>Thu, 27 Jun 2013 05:31:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Cytokinetics and Astellas Announce Collaboration in the Field of Skeletal Muscle Activation]]></title>
      <link>http://phx.corporate-ir.net/phoenix.zhtml?c=142156&amp;p=RssLanding&amp;cat=news&amp;id=1832609</link>
      <description><![CDATA[Collaboration Will Focus on Expanding the New Frontier of Muscle Biology   Cytokinetics is Eligible to Receive Over $40 Million During the Initial Two Years in Addition to Over $450 Million in Potential Milestone Payments plus Royalties   South San Francisco, CA, and Tokyo, June 25, 2013 - Cytokinetics, Incorporated (NASDAQ:CYTK) and Astellas Pharma Inc. (Tokyo Stock Exchange: 4503, &quot;Astellas&quot;) announced today a collaboration focused on the research, development and commercialization of skeletal muscle activators. ]]></description>
      <pubDate>Tue, 25 Jun 2013 11:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[CTI Issues Statement Regarding Tosedostat Clinical Trial]]></title>
      <link>http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&amp;p=RssLanding&amp;cat=news&amp;id=1832542</link>
      <description><![CDATA[SEATTLE, June 25, 2013 /PRNewswire/ --]]></description>
      <pubDate>Tue, 25 Jun 2013 05:31:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[CTI Issues Statement Regarding Tosedostat Clinical Trial]]></title>
      <link>http://phx.corporate-ir.net/phoenix.zhtml?c=92775&amp;p=RssLanding&amp;cat=news&amp;id=1832542</link>
      <description><![CDATA[SEATTLE, June 25, 2013 /PRNewswire/ --]]></description>
      <pubDate>Tue, 25 Jun 2013 05:31:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Cytokinetics Announces 1-for-6 Reverse Stock Split]]></title>
      <link>http://phx.corporate-ir.net/phoenix.zhtml?c=142156&amp;p=RssLanding&amp;cat=news&amp;id=1832526</link>
      <description><![CDATA[South San Francisco, CA]]></description>
      <pubDate>Tue, 25 Jun 2013 00:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[ARIAD Honored with Gold Stevie]]></title>
      <link>http://phx.corporate-ir.net/phoenix.zhtml?c=118422&amp;p=RssLanding&amp;cat=news&amp;id=1830999</link>
      <description><![CDATA[CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 18, 2013--
      ARIAD
      Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it was
      honored with two Gold Stevie]]></description>
      <pubDate>Tue, 18 Jun 2013 21:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[ARIAD Honored with Gold Stevie]]></title>
      <link>http://investor.ariad.com/phoenix.zhtml?c=118422&amp;p=RssLanding&amp;cat=news&amp;id=1830999</link>
      <description><![CDATA[CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 18, 2013--
      ARIAD
      Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it was
      honored with two Gold Stevie]]></description>
      <pubDate>Tue, 18 Jun 2013 21:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[ARIAD Honored with Gold Stevie]]></title>
      <link>http://phx.corporate-ir.net/phoenix.zhtml?c=118422&amp;p=RssLanding&amp;cat=news&amp;id=1830928</link>
      <description><![CDATA[CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 18, 2013--
      ARIAD
      Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it was
      honored with two Gold Stevie]]></description>
      <pubDate>Tue, 18 Jun 2013 18:14:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Cytokinetics Announces Results From ATOMIC-AHF Will Be Presented At Late Breaking Clinical Trials Session At The European Society Of Cardiology Congress 2013]]></title>
      <link>http://phx.corporate-ir.net/phoenix.zhtml?c=142156&amp;p=RssLanding&amp;cat=news&amp;id=1830670</link>
      <description><![CDATA[South San Francisco, CA]]></description>
      <pubDate>Tue, 18 Jun 2013 11:30:00 +0000</pubDate>
    </item>
  </channel>
</rss>
